Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
Procedure
IMD Drug Screening for Adenoid Cystic Carcinoma
This trial tests a tiny device that releases multiple drugs directly into tumors in patients with a specific type of head and neck cancer. The device helps doctors find out which drugs are most effective by analyzing it after it is removed during surgery.
Monoclonal Antibodies
XMT-1660 for Breast Cancer
This trial tests a new drug called XMT-1660 to see if it is safe and what side effects it might have. It focuses on patients whose cancer has come back, spread locally, or spread throughout the body. The study will first find a safe dose and then check if this dose helps treat solid tumors.
Popular Filters
Trials for ACC Patients
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Anti-metabolites
Pemetrexed + Pembrolizumab for Salivary Gland Cancer
This trial tests the effect of combining two cancer treatments: chemotherapy drug pemetrexed with immunotherapy drug pembrolizumab. The purpose is to see if this combo is more effective than pemetrexed alone in treating patients with recurrent or metastatic salivary gland cancer.
CAR T-cell Therapy
P-PSMA-101 CAR-T Cells for Prostate Cancer
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
This trial is testing lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. Researchers aim to see if these drugs are effective and safe for these patients. Lenvatinib and pembrolizumab have shown promising results in treating various advanced cancers, including thyroid, liver, endometrial, and gastric cancers.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Trials for Cancer Patients
CAR T-cell Therapy
P-PSMA-101 CAR-T Cells for Prostate Cancer
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
MYB mRNA degrader
REM-422 for Advanced Cancer
This trial is testing REM-422, an oral medicine, in people with advanced Adenoid Cystic Carcinoma (ACC) that has returned or spread. REM-422 aims to reduce a protein needed for cancer growth by breaking down its mRNA. The study will determine the best dose and evaluate its safety and effectiveness.
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Trials for Metastatic Patients
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Anti-metabolites
Pemetrexed + Pembrolizumab for Salivary Gland Cancer
This trial tests the effect of combining two cancer treatments: chemotherapy drug pemetrexed with immunotherapy drug pembrolizumab. The purpose is to see if this combo is more effective than pemetrexed alone in treating patients with recurrent or metastatic salivary gland cancer.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
This trial is testing lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. Researchers aim to see if these drugs are effective and safe for these patients. Lenvatinib and pembrolizumab have shown promising results in treating various advanced cancers, including thyroid, liver, endometrial, and gastric cancers.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
Tyrosine Kinase Inhibitor
Lenvatinib for Adenoid Cystic Carcinoma
This trial is testing lenvatinib, a pill that aims to stop cancer cells from growing and reduce their blood supply, in patients with adenoid cystic carcinoma. Researchers want to see if it can shrink the tumors by at least one-quarter. Lenvatinib has shown promise in treating various solid tumors, including adenoid cystic carcinoma.
Trials With No Placebo
Notch Inhibitor
AL101 Before Surgery for Adenoid Cystic Carcinoma
This trial studies the effects of AL101, a drug given through an IV drip, on patients with notch activated adenoid cystic cancer. The drug aims to stop the cancer cells from growing by blocking necessary enzymes. The goal is to see if AL101 can help control this specific type of cancer before surgery.
Anti-metabolites
Pemetrexed + Pembrolizumab for Salivary Gland Cancer
This trial tests the effect of combining two cancer treatments: chemotherapy drug pemetrexed with immunotherapy drug pembrolizumab. The purpose is to see if this combo is more effective than pemetrexed alone in treating patients with recurrent or metastatic salivary gland cancer.
CAR T-cell Therapy
P-PSMA-101 CAR-T Cells for Prostate Cancer
This trial tests a treatment where a patient's immune cells are modified to better fight advanced prostate and salivary gland cancers. The modified cells are reintroduced into the body to target and destroy cancer cells.
Tyrosine Kinase Inhibitor
Lenvatinib + Pembrolizumab for Salivary Gland Cancer
This trial is testing lenvatinib and pembrolizumab in patients with advanced Adenoid Cystic Carcinoma or other salivary gland cancers that have come back or spread. Lenvatinib stops cancer cells from growing, while pembrolizumab helps the immune system attack the cancer. Researchers aim to see if these drugs are effective and safe for these patients. Lenvatinib and pembrolizumab have shown promising results in treating various advanced cancers, including thyroid, liver, endometrial, and gastric cancers.
Monoclonal Antibodies
ONC-392 + Pembrolizumab for Non-Small Cell Lung Cancer
This trial tests ONC-392, an antibody that helps the immune system fight cancer, in patients with advanced or spreading tumors who haven't responded to other treatments. It works by blocking a protein that usually keeps immune responses in check, making it easier for the body to attack cancer cells.
View More Related Trials
Frequently Asked Questions
Introduction to adenoid cystic carcinoma
What are the top hospitals conducting adenoid cystic carcinoma research?
When it comes to advancing the understanding and treatment of adenoid cystic carcinoma, several esteemed hospitals are leading the way. In Boston's medical landscape, Dana Farber Cancer Institute takes the helm with five ongoing clinical trials focused specifically on this rare cancer type. They have made significant progress since their first recorded trial in 2017. Memorial Sloan Kettering Cancer Center in New york follows closely behind, also boasting five active adenoid cystic carcinoma trials and a history of ten completed studies dating back to their inaugural trial in 2004.
Meanwhile, Massachusetts General Hospital has four ongoing clinical trials dedicated to adenoid cystic carcinoma and has conducted a total of five studies since initiating research in this area in 2011. Brigham and Women's Hospital is another notable institution contributing to the field with three active clinical trials for this condition; they began exploring adenoid cystic carcinoma through their first trial just last year in 2021.
Even outside these major cities, dedication remains strong as seen at University of Cincinnati Medical Center where two current adenoid cystic carcinoma clinical trials are underway. This center has already played a crucial part by conducting two previous investigations into this relatively uncommon cancer type starting from their initial study recorded back in 2020.
These hospitals serve as beacons of hope for individuals battling an often challenging disease like adenoid cystic carcinoma. Through cutting-edge research and innovative treatments explored within these clinical trials, medical professionals strive diligently towards improving outcomes for patients affected by this particular form of cancer — bringing us one step closer to conquering it entirely
Which are the best cities for adenoid cystic carcinoma clinical trials?
When it comes to adenoid cystic carcinoma clinical trials, several cities have emerged as leaders in research and development. Boston, Massachusetts leads the way with 13 active trials investigating treatments like IMD PLACEMENT + SURGICAL RESECTION + ADJUVANT TREATMENT ARM, 9-ING-41, and SBRT. New york, New York follows closely behind with 8 ongoing studies focusing on interventions such as Lenvatinib, VMD-928 (in different formulations), and Pembrolizumab. Anchorage, Alaska also has 8 active trials analyzing treatment options including Nivolumab. Lastly, Houston, Texas and Basking Ridge, New jersey both have 6 active trials exploring various therapies for adenoid cystic carcinoma such as AL101, Regorafenib alongside others. These cities offer individuals battling this disease access to cutting-edge clinical trials that may pave the way for improved outcomes and hope for a better future.
Which are the top treatments for adenoid cystic carcinoma being explored in clinical trials?
Clinical trials are exploring various treatments to combat adenoid cystic carcinoma, a challenging form of cancer. Among the top contenders is AL101, currently participating in two active trials specifically focused on this type of carcinoma. Since its initial listing in 2018, it has been involved in a total of two clinical trials dedicated to addressing adenoid cystic carcinoma. Another promising treatment option is lenvatinib with two ongoing clinical trials and four all-time studies targeting this specific cancer since its introduction in 2015. SGN-B7H4V and 9-ING-41 also show potential as they each participate in one active trial for adenoid cystic carcinoma, with respective listings beginning in 2022 and 2021. These innovative treatments offer hope for patients battling adenoid cystic carcinoma as researchers continue their efforts towards finding effective solutions for this challenging disease.
What are the most recent clinical trials for adenoid cystic carcinoma?
Promising developments have emerged in the field of adenoid cystic carcinoma through recent clinical trials. One notable study investigated the combination of CB-103 and Venetoclax, intended for patients with this specific type of cancer. This experimental treatment has progressed to Phase 2 after demonstrating potential efficacy during Phase 1 testing. Additionally, another trial explored the use of Amivantamab as a therapeutic option for adenoid cystic carcinoma, reaching Phase 2 status based on promising preliminary results. These advances offer hope for improved outcomes in patients fighting against this challenging disease.
What adenoid cystic carcinoma clinical trials were recently completed?
Several notable clinical trials investigating treatments for adenoid cystic carcinoma have recently concluded, marking significant progress in the field. In March 2020, Elevar Therapeutics completed a trial assessing the efficacy of Rivoceranib. This was followed by a trial sponsored by M.D. Anderson Cancer Center, which wrapped up in July 2019 and examined the potential benefits of Axitinib. Additionally, Prelude Therapeutics conducted a trial on PRT543 that reached completion in February 2019. It is worth noting that an earlier study sponsored by Dana-Farber Cancer Institute investigated Pembrolizumab and successfully concluded in April 2017. These advancements underscore ongoing efforts to find effective therapies for adenoid cystic carcinoma, offering hope to patients affected by this challenging malignancy.